

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6367240

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	IMMUNOCOPEA LIMITED	12/31/2013
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	INFIRST HEALTHCARE LIMITED	
<b>Street Address:</b>	CENTRAL POINT, 45 BEECH STREET	
<b>City:</b>	LONDON	
<b>State/Country:</b>	UNITED KINGDOM	
<b>Postal Code:</b>	EC2Y 8AD	
<b>PROPERTY NUMBERS Total: 1</b>		
	<b>Property Type</b>	<b>Number</b>
	Application Number:	16818668
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	949-345-5678	
<b>Email:</b>	dean.stathakis@ultimatedgeip.com	
<b>Correspondent Name:</b>	DEAN G. STATHAKIS	
<b>Address Line 1:</b>	2372 MORSE AVENUE	
<b>Address Line 2:</b>	SUITE 252	
<b>Address Line 4:</b>	IRVINE, CALIFORNIA 92614-6234	
<b>ATTORNEY DOCKET NUMBER:</b>	UEINF1-0033USC10	
<b>NAME OF SUBMITTER:</b>	DEAN G. STATHAKIS	
<b>SIGNATURE:</b>	/Dean G. Stathakis/	
<b>DATE SIGNED:</b>	10/26/2020	
<b>Total Attachments: 8</b>		
source=2013-12-31-Assignment-Immunocopea-infirstHealthcare-Executed-REDACTED#page1.tif		
source=2013-12-31-Assignment-Immunocopea-infirstHealthcare-Executed-REDACTED#page2.tif		
source=2013-12-31-Assignment-Immunocopea-infirstHealthcare-Executed-REDACTED#page3.tif		
source=2013-12-31-Assignment-Immunocopea-infirstHealthcare-Executed-REDACTED#page4.tif		
source=2013-12-31-Assignment-Immunocopea-infirstHealthcare-Executed-REDACTED#page5.tif		

source=2013-12-31-Assignment-Immunocopea-infirstHealthcare-Executed-REDACTED#page6.tif

source=2013-12-31-Assignment-Immunocopea-infirstHealthcare-Executed-REDACTED#page7.tif

source=2013-12-31-Assignment-Immunocopea-infirstHealthcare-Executed-REDACTED#page8.tif

Dated 31st December 2013

(1) IMMUNOCOPEA LIMITED

- and -

(2) INFIRST HEALTHCARE LIMITED

---

## INTELLECTUAL PROPERTY ASSIGNMENT AND TRANSFER AGREEMENT

---

DAC Beachcroft LLP  
100 Fetter Lane London EC4A 3EN UK  
tel: +44 (0) 20 7242 1011 fax: +44 (0) 20 7831 8630  
DX 45 London

113311805\_1.DOC

PATENT  
REEL: 054162 FRAME: 0186 *14*

THIS ASSIGNMENT (this "Assignment") is dated \_\_\_\_\_ 31st \_\_\_\_\_ December 2013.

## Parties

- (1) **IMMUNOCOPEA LIMITED** incorporated and registered in the Republic of Ireland with company number 489367 whose registered office is at 70 Sir John Rogerson's Quay, Dublin 2, The Republic of Ireland (the "Assignor"); and
- (2) **INFIRST HEALTHCARE LIMITED** a company incorporated under the laws of England and Wales with company number: 08077285 and whose registered office is at 100 Fetter Lane, London, EC4A 1BN, UK (the "Assignee").

## 1. INTERPRETATION

1.1 In this Assignment, the following words have the following meanings:

**"Improvements"** any improvement, enhancement or modification to any products falling within the scope of any of the claims of the Patents and which relates to the use of ibuprofen to treat pain and inflammatory diseases;

**"Patents"** all intellectual property rights under the patents and/or applications described in the Schedule hereto together with all continuations, continuations in part and divisionals of such applications and all re-issues, re-examinations and extensions of such patent(s).

## 2. ASSIGNMENT

2.1 For good and valuable consideration [REDACTED] the Assignor hereby ASSIGNS to the Assignee, full title to:

- 2.1.1 the Patents;
- 2.1.2 the Improvements; and
- 2.1.3 all of Assignor's right, title and interest in and to all intellectual property rights and know-how which it holds now or in the future including without limitation such rights relating to the use of ibuprofen to treat pain and inflammatory disease;

and the Assignor hereby TRANSFERS to the Assignee all of its other assets in relation to the use of ibuprofen in the treatment of pain and inflammatory disease (except for plant and machinery and employment agreements) including without limitation, confidential information (e.g. data and manufacturing formulae), the benefit of relevant agreements with third parties and regulatory applications and submissions which have been made in the Assignor's name (whether complete or incomplete).

### 3. THIRD PARTY LIABILITIES

The Assignee shall (as primary obligor) pay, settle and/or discharge any payments, costs, expenses, obligations and liabilities of any description due from time to time after the date hereof (referred to collectively as the "**Liabilities**") to third parties in respect of the Patents, Improvements and intellectual property rights assigned, and other assets transferred, under clause 2.1 above provided that the Assignor delivers valid documentary evidence of the Liability (e.g. in the form of an invoice), and to the extent that such Liabilities are not paid, settled and/or discharged by the Assignee, the Assignee shall indemnify and keep indemnified the Assignor and hold the Assignor harmless from and against all losses (whether direct or indirect) damages, costs, actions, awards, penalties, fines, proceedings, claims, demands and liabilities (including without limitation, reasonable legal and other professional fees and expenses) which the Assignor may suffer, sustain, incur, pay or be put to by reason or on account of or arising from the Assignee's failure to pay, settle or otherwise discharge the Liabilities.

### 4. GOVERNING LAW AND JURISDICTION

- 4.1 This Assignment and any disputes or claims arising out of or in connection with it or its subject matter or formation (including non-contractual disputes or claims) are governed by and construed in accordance with the laws of England.
- 4.2 The parties irrevocably agree that the courts of England have exclusive jurisdiction to settle any dispute or claim that arises out of or in connection with this agreement or its subject matter or formation (including non-contractual disputes or claims).

### 5. MISCELLANEOUS

- 5.1 This Assignment may be executed in one or more counterparts, each of which, shall be deemed to be an original but all of which together shall constitute one and the same instrument.

This document has been signed on behalf of the parties hereto and is delivered and takes effect on the date stated at the beginning of it.

## SCHEDULE

## Patents

Reference #	Title	CNTRY	Serial #	Filed Date	Patent #	Issue Date	Status	Category	Expiration
1958652.00002GB	METHOD OF PREPARING OILY IBUPROFEN FORMULATION	GB	1101237.9	04/02/2011			PENDING	BC1054	04/02/2031
1958652.00002.1GB	SOLID DOSE FORM	GB	1113730.4	10/08/2011			PENDING	BC1054	06/05/2021
1958652.00002US	COMPOSITIONS AND METHODS FOR TREATING CHRONIC INFLAMMATION AND INFLAMMATORY DISEASES	US	13,365,824	03/02/2012			PUBLISHED	BC1054	03/02/2032
1958652.00002WO	METHOD OF PREPARING A COMPOSITION	WO	PCT/GB2012/050242	03/02/2012			PUBLISHED	BC1054	04/02/2014
1958652.00003GB	HYPERLIPIDEMIA	GB	1113729.6	10/08/2011			PENDING	BC1054	10/08/2031
1958652.00003WO	COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASES	WO	PCT/GB2013/060241	03/02/2012			PUBLISHED	BC1054	
1958652.00011AU	TREATMENT OF MICROBIAL INFECTIONS	AU	2010317727	05/11/2010			PENDING	BC1054	09/11/2030
1958652.00011BR	TREATMENT OF MICROBIAL INFECTIONS	BR	BR1120120112519	05/11/2010			PENDING	BC1054	09/11/2030
1958652.00011CA	TREATMENT OF MICROBIAL INFECTIONS	CA	2,750,614	05/11/2010			PENDING	BC1054	09/11/2030
1958652.00011CN	TREATMENT OF MICROBIAL INFECTIONS	CN	201080061247.4	05/11/2010			PUBLISHED	BC1054	09/11/2030


1958652.00011EG	TREATMENT OF MICROBIAL INFECTIONS	EG	8502013PCT	09/11/2010		PENDING	BC1054	09/11/2030
1958652.00011EP	TREATMENT OF MICROBIAL INFECTIONS	EP	10773965.8	09/11/2010		PUBLISHED	BC1054	09/11/2030
1958652.00011GB	TREATMENT OF MICROBIAL INFECTIONS	GB	1001837.2	04/02/2010		PUBLISHED	BC1054	04/02/2030
1958652.00011IL	TREATMENT OF MICROBIAL INFECTIONS	IL	219771	09/11/2010		PENDING	BC1054	09/11/2030
1958652.00011IN	TREATMENT OF MICROBIAL INFECTIONS	IN	5114/DELNP/2012	09/11/2010		PENDING	BC1054	09/11/2030
1958652.00011JP	TREATMENT OF MICROBIAL INFECTIONS	JP	2012-538406	09/11/2010		PENDING	BC1054	09/11/2030
1958652.00011MX	TREATMENT OF MICROBIAL INFECTIONS	MX	MX/a/2012/005551	09/11/2010		PENDING	BC1054	09/11/2030
1958652.00011NZ	TREATMENT OF MICROBIAL INFECTIONS	NZ	596946	09/11/2010		PENDING	BC1054	09/11/2030
1958652.00011RU	TREATMENT OF MICROBIAL INFECTIONS	RU	2012124039	09/11/2010		PENDING	BC1054	09/11/2030
1958652.00011SG	TREATMENT OF MICROBIAL INFECTIONS	SG	201203464.2	09/11/2010		PENDING	BC1054	09/11/2030
1958652.00011TH	TREATMENT OF MICROBIAL INFECTIONS	TH	1201002197	09/11/2010		PENDING	BC1054	09/11/2030
1958652.00011UA	TREATMENT OF MICROBIAL INFECTIONS	UA	201208985	09/11/2010		PENDING	BC1054	09/11/2030
1958652.00011US	TREATMENT OF MICROBIAL INFECTIONS	US	13508.534	11/05/2012		PENDING	BC1054	
1958652.00011WO	TREATMENT OF MICROBIAL INFECTIONS	WO	PCT/GB2010/051858	09/11/2010		NAT PHASE	BC1054	11/11/2012
1958652.00011ZA	TREATMENT OF MICROBIAL INFECTIONS	ZA	2012/4249	09/11/2010		PENDING	BC1054	09/11/2030

1958652.00012AU	TREATMENT OF RESPIRATORY DISORDERS	AU	2012/12/256	04/02/2011		PENDING	BC1054	04/02/2031
1958652.00012BR	TREATMENT OF RESPIRATORY DISORDERS	BR	BR1120120194574	04/02/2011		PENDING	BC1054	04/02/2031
1958652.00012CA	TREATMENT OF RESPIRATORY DISORDERS	CA	2188766	04/02/2011		PENDING	BC1054	04/02/2031
1958652.00012CN	TREATMENT OF RESPIRATORY DISORDERS	CN	201180018052.6	04/02/2011		PENDING	BC1054	04/02/2031
1958652.00012EP	TREATMENT OF RESPIRATORY DISORDERS	EP	11102694.8	04/02/2011		PUBLISHED	BC1054	04/02/2031
1958652.00012IN	TREATMENT OF RESPIRATORY DISORDERS	IN	7715DELNP/2012	04/02/2011		PENDING	BC1054	04/02/2031
1958652.00012JP	TREATMENT OF RESPIRATORY DISORDERS	JP	2012-551685	04/02/2011		PENDING	BC1054	04/02/2031
1958652.00012MX	TREATMENT OF RESPIRATORY DISORDERS	MX	MX/a/2012/0093652	04/02/2011		PENDING	BC1054	04/02/2031
1958652.00012NZ	TREATMENT OF RESPIRATORY DISORDERS	NZ	601594	04/02/2011		PENDING	BC1054	04/02/2031
1958652.00012RU	TREATMENT OF RESPIRATORY DISORDERS	RU	2012137785	04/02/2011		PENDING	BC1054	04/02/2031
1958652.00012SG	TREATMENT OF RESPIRATORY DISORDERS	SG	201205786.5	04/02/2011		PENDING	BC1054	04/02/2031
1958652.00012US	TREATMENT OF RESPIRATORY DISORDERS	US	13576,758	02/08/2012		PENDING	BC1054	04/02/2031
1958652.00012WD	TREATMENT OF RESPIRATORY DISORDERS	WO	PCT/GB2011/050169	04/02/2011		NAT PHASE	BC1054	05/02/2012
1958652.00012ZA	TREATMENT OF RESPIRATORY DISORDERS	ZA	2012/5829	04/02/2011		PENDING	BC1054	04/02/2031



1358652.00014GB	TREATMENT OF RESPIRATORY DISORDERS	GB	1016289.7	28/10/2010	PENDING	BC1054	29/10/2030
1358652.00014.1GB	INFLAMMATORY DISEASE	GB	1113724.6	10/08/2011	PUBLISHED	BC1054	08/05/2021
1358652.00014WO	INFLAMMATORY DISEASE	WO	PCT/GB2011062115	31/10/2011	PUBLISHED	BC1054	29/10/2013


SIGNED on behalf of IMMUNOCOPEA LIMITED )  
a company incorporated under the laws )  
of the Republic of Ireland by Manfred Scheske, )  
being a person who, in accordance with the )  
laws of that jurisdiction, is acting under the )  
authority of the company in the presence of: )

  
Director

WITNESS:

Signature: Mary O'Hagan  
Name: MARY O'HAGAN  
Address: 45 BEECH STREET,  
LONDON EC2Y 8AA  
Occupation: OFFICE MANAGER  
(PLEASE COMPLETE IN CAPITALS)

SIGNED on behalf of INFIRST HEALTHCARE )  
LIMITED a company incorporated under the laws of )  
England and Wales, acting by Andrew Waters )

  
Director